Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash & Equivalents (2022 - 2026)

HeartSciences (HSCS) has disclosed Cash & Equivalents for 4 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 51.85% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Oct 2025, down 51.85%, and an annual FY2025 reading of $1.1 million, down 81.09% over the prior year.
  • Cash & Equivalents was $2.0 million for Q4 2025 at HeartSciences, down from $2.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $7.1 million in Q1 2024 and bottomed at $100144.0 in Q4 2023.
  • Average Cash & Equivalents over 4 years is $2.8 million, with a median of $2.6 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents crashed 96.74% in 2023, then soared 3946.29% in 2024.
  • Year by year, Cash & Equivalents stood at $3.1 million in 2022, then plummeted by 96.74% to $100144.0 in 2023, then skyrocketed by 3946.29% to $4.1 million in 2024, then plummeted by 51.85% to $2.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for HSCS at $2.0 million in Q4 2025, $2.8 million in Q3 2025, and $1.1 million in Q2 2025.